Background: The aim of this study was to analyze the associations between sexuality, quality of life, treatment discontinuation, and survival in recurrent ovarian cancer (OC). Methods: Raw data from various phase II/III studies, including the questionnaires EORTC-QLQ-C30 and QLQ-OV28, were included. Data from the meta-analysis were calculated using logistic and Cox regression. Results: Data on sexuality were available for 644 patients. A total of 162 patients had an interest in sex and were sexually active (Group A). A total of 45 patients had an interest in sex and were sexually not active (Group I) and 437 patients had no interest in sex and were not sexually active (Group N). Group A was younger in median age (age at randomization), at 57 years, than Group I, at 60 years, and Group N, at 65 years (p< 0.001). Group A had a better ECOG performance status and fewer recurrences (allp< 0.001). FIGO stage, grading, and BMI were not associated with interest in sex and sexual activity. Group A showed higher scores in role, body, and social function (allp< 0.001), emotional functionality (p< 0.002), and body image (p= 0.012). In addition, Group A reported less pain, less peripheral neuropathy, and less fatigue (allp< 0.001). There was no association with the premature discontinuation of chemotherapy. Group A showed better survival rates compared to group N (22.3 months vs. 17.4 months,p< 0.001). Conclusions: Physicians should routinely address the topic of sexuality with ovarian cancer patients. Sexuality appears to be a marker for quality of life as well as overall survival.
背景：本研究旨在分析复发性卵巢癌（OC）患者的性功能、生活质量、治疗中断与生存期之间的关联。方法：研究整合了多项II/III期临床试验的原始数据，其中包含欧洲癌症研究与治疗组织生活质量核心量表（EORTC-QLQ-C30）及卵巢癌特异性模块（QLQ-OV28）的问卷结果。通过逻辑回归与Cox回归模型对荟萃分析数据进行计算。结果：共644例患者提供性功能相关数据。其中162例患者对性有兴趣且保持性活跃（A组）；45例患者对性有兴趣但未保持性活跃（I组）；437例患者对性无兴趣且未保持性活跃（N组）。A组中位年龄（随机分组时）为57岁，显著低于I组（60岁）和N组（65岁）（p<0.001）。A组患者ECOG体能状态更佳，复发次数更少（均p<0.001）。FIGO分期、肿瘤分级及体重指数与性兴趣及性活跃度无显著关联。A组在角色功能、躯体功能、社会功能（均p<0.001）、情绪功能（p<0.002）及体像感知（p=0.012）维度评分更高。此外，A组患者疼痛程度、周围神经病变及疲劳感均显著较轻（均p<0.001）。性功能状态与提前终止化疗无显著关联。与N组相比，A组患者生存期更优（22.3个月 vs. 17.4个月，p<0.001）。结论：临床医生应将性功能评估纳入卵巢癌患者的常规诊疗。性功能状态可作为生活质量和总生存期的重要预测指标。
肿瘤(癌症)患者之家